Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole for recovery after androgen abuse cessation
ACTRN12621001751864Phase 4Not yet recruiting
- Sponsor
- National Health and Medical Research Council
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in anabolic-androgenic steroid use disorder (AASUD) comparing Letrozole with Placebo (2 arms). Primary endpoint: Composite measure of recovery based on serum LH and FSH. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
letrozole
03
Conditions
anabolic-androgenic steroid use disorder (AASUD)
Beyond the preview
Go deeper on ACTRN12621001751864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001751864.